Attenuated Salmonella enterica Serovar Typhi Expressing Urease Effectively Immunizes Mice against Helicobacter pylori Challenge as Part of a Heterologous Mucosal Priming-Parenteral Boosting Vaccination Regimen
Open Access
- 1 September 2002
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 70 (9) , 5096-5106
- https://doi.org/10.1128/iai.70.9.5096-5106.2002
Abstract
Recombinant vaccine strains of Salmonella enterica serovar Typhi capable of expressing Helicobacter pylori urease were generated by transforming strains CVD908 and CVD908-htrA with a plasmid harboring the ureAB genes under the control of an in vivo-inducible promoter. The plasmid did not interfere with the ability of either strain to replicate and persist in human monocytic cells or with their transient colonization of mouse lungs. When administered to mice intranasally, both recombinant strains elicited antiurease immune responses skewed towards a Th1 phenotype. Vaccinated mice exhibited strong immunoglobulin G2a (IgG2a)-biased antiurease antibody responses as well as splenocyte populations capable of proliferation and gamma interferon (IFNγ) secretion in response to urease stimulation. Boosting of mice with subcutaneous injection of urease plus alum enhanced immune responses and led them to a more balanced Th1/Th2 phenotype. Following parenteral boost, IgG1 and IgG2a antiurease antibody titers were raised significantly, and strong urease-specific splenocyte proliferative responses, accompanied by IFNγ as well as interleukin-4 (IL-4), IL-5, and IL-10 secretion, were detected. Neither immunization with urease-expressing S. enterica serovar Typhi alone nor immunization with urease plus alum alone conferred protection against challenge with a mouse-adapted strain of H. pylori; however, a vaccination protocol combining both immunization regimens was protective. This is the first report of effective vaccination against H. pylori with a combined mucosal prime-parenteral boost regimen in which serovar Typhi vaccine strains are used as antigen carriers. The significance of these findings with regard to development of a human vaccine against H. pylori and modulation of immune responses by heterologous prime-boost immunization regimens is discussed.Keywords
This publication has 82 references indexed in Scilit:
- Construction and Characterization of Genetically Defined aro omp Mutants of Enterotoxigenic Escherichia coli and Preliminary Studies of Safety and Immunogenicity in HumansInfection and Immunity, 2001
- Selection for Urease Activity during Helicobacter pylori Infection of Rhesus Macaques ( Macaca mulatta )Infection and Immunity, 2001
- Analysis of host responses of guinea pigs during Helicobacter pylori infectionFEMS Immunology & Medical Microbiology, 2001
- Safety and Immune Responses to Attenuated Salmonella enterica Serovar Typhi Oral Live Vector Vaccines Expressing Tetanus Toxin Fragment CClinical Immunology, 2000
- Immunization with Recombinant Helicobacter pylori Urease in Specific-Pathogen-Free Rhesus Monkeys ( Macaca mulatta )Infection and Immunity, 2000
- Parenteral Adjuvant Activities ofEscherichia coliHeat-Labile Toxin and Its B Subunit for Immunization of Mice against GastricHelicobacter pyloriInfectionInfection and Immunity, 2000
- Oral immunization with recombinant Helicobacter pylori urease confers long-lasting immunity against Helicobacter felis infectionVaccine, 1999
- Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvantVaccine, 1998
- Use of the nirB Promoter to Direct the Stable Expression of Heterologous Antigens in Salmonella Oral Vaccine Strains: Development of a Single–Dose Oral Tetanus VaccineNature Biotechnology, 1992
- In vitro characterization of Salmonella typhi mutant strains for live oral vaccinesVaccine, 1990